{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:24Z","timestamp":1793924544541,"version":"4.8.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872735"],"award-info":[{"award-number":["81872735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030313046"],"award-info":[{"award-number":["2018A030313046"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115194","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T03:02:10Z","timestamp":1675911730000},"page":"115194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Advances in the development of phosphodiesterase 7 inhibitors"],"prefix":"10.1016","volume":"250","author":[{"given":"Jia-Xi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-5913","authenticated-orcid":false,"given":"Zhong-Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115194_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2023.115194_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nn.4066","article-title":"The role of ventral striatal cAMP signaling in stress-induced behaviors","volume":"18","author":"Plattner","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115194_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm.4011","article-title":"Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling","volume":"22","author":"Myeku","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115194_bib4","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1021\/acs.jmedchem.9b02170","article-title":"Advances in the development of phosphodiesterase-4 inhibitors","volume":"63","author":"Peng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib5","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","article-title":"Novel phosphodiesterase inhibitors for cognitive improvement in Alzheimer's Disease","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejmech.2018.03.046","article-title":"Inhibitors of phosphodiesterase as cancer therapeutics","volume":"150","author":"Peng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/13543776.2014.968127","article-title":"cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases","volume":"24","author":"Martinez","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115194_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/24884","article-title":"Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP","volume":"396","author":"de Rooij","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115194_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2023.115194_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108694","article-title":"Phosphodiesterase 7(PDE7): a unique drug target for central nervous system diseases","volume":"196","author":"Chen","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115194_bib11","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1021\/jm501090m","article-title":"Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors","volume":"57","author":"Garcia","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib12","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1016\/S0021-9258(18)31474-1","article-title":"Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae","volume":"268","author":"Michaeli","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cmdc.200900043","article-title":"Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors","volume":"4","author":"Castano","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115194_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/0929867324666170116125159","article-title":"PDE7-Selective and dual inhibitors: advances in chemical and biological research","volume":"24","author":"Jankowska","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib15","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bmcl.2015.03.031","article-title":"2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy","volume":"25","author":"Endo","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115194_bib17","doi-asserted-by":"crossref","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","article-title":"Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart","volume":"272","author":"Han","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115194_bib19","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1210\/en.2018-00017","article-title":"Multiple cAMP phosphodiesterases act together to prevent premature oocyte meiosis and ovulation","volume":"159","author":"Vigone","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2023.115194_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1517\/14728222.2013.798304","article-title":"Targeting cAMP in chronic lymphocytic leukemia: a pathway-dependent approach for the treatment of leukemia and lymphoma","volume":"17","author":"Murray","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2023.115194_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s10787-022-01072-1","article-title":"Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders","volume":"30","author":"Khan","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejmech.2023.115194_bib22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ejcb.2006.01.003","article-title":"Protein kinase A targeting and activation as seen by small-angle solution scattering","volume":"85","author":"Trewhella","year":"2006","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115194_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113823","article-title":"Elevated intracellular cAMP concentration mediates growth suppression in glioma cells","volume":"174","author":"Safitri","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jaci.2010.08.014","article-title":"Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma","volume":"126","author":"Jin","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115194_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/JEP.S242961","article-title":"New avenues for phosphodiesterase inhibitors in asthma","volume":"13","author":"Matera","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14656566.2019.1570132","article-title":"An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma","volume":"20","author":"Al-Sajee","year":"2019","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115194_bib27","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","article-title":"Phosphodiesterase inhibitors in airways disease","volume":"533","author":"Chung","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1465-9921-10-39","article-title":"A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice","volume":"10","author":"Fortin","year":"2009","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2023.115194_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-94-007-4549-0_8","article-title":"Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized Guinea pigs","volume":"756","author":"Mokry","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2023.115194_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejphar.2006.08.023","article-title":"Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models","volume":"550","author":"Yamamoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib32","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2249.2002.01856.x","article-title":"Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors","volume":"128","author":"Nakata","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejmech.2023.115194_bib33","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1073\/pnas.0806152105","article-title":"Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115194_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2006.11.079","article-title":"Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059","volume":"559","author":"Yamamoto","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2006.05.007","article-title":"The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo","volume":"541","author":"Yamamoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/biomedicines9070703","article-title":"Neuroinflammation in ischemic stroke: inhibition of cAMP-specific phosphodiesterases (PDEs) to the rescue","volume":"9","author":"Ponsaerts","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2023.115194_bib37","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ejmech.2007.10.027","article-title":"CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example","volume":"43","author":"Castro","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib38","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.1021\/jm5008215","article-title":"Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a dew series of potent phosphodiesterase 7 inhibitors","volume":"57","author":"Kawai","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ejps.2012.01.007","article-title":"5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin","volume":"45","author":"Perez","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2023.115194_bib40","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1021\/jm201463v","article-title":"5-Imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3","volume":"55","author":"Palomo","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/syn.1043","article-title":"Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs","volume":"40","author":"Miro","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.ejmech.2023.115194_bib42","first-page":"458","article-title":"Phosphodiesterase 7 inhibition activates adult neurogenesis in Hippocampus and subventricular zone in vitro and in vivo, stem","volume":"35","author":"Morales-Garcia","year":"2017","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.115194_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017240","article-title":"Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease","volume":"6","author":"Morales-Garcia","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115194_bib44","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1016\/j.bmcl.2012.07.077","article-title":"Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model","volume":"22","author":"Banerjee","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","article-title":"Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization","volume":"182","author":"Perez-Torres","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2023.115194_bib46","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.13192","article-title":"PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis","volume":"172","author":"Mestre","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib47","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","article-title":"Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease","volume":"34","author":"Perez-Gonzalez","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2023.115194_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2020.107357","article-title":"Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory","volume":"177","author":"McQuown","year":"2021","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.ejmech.2023.115194_bib49","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1007\/s12031-020-01569-w","article-title":"A systematic and comprehensive review on disease-causing genes in amyotrophic lateral sclerosis","volume":"70","author":"Srinivasan","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115194_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2011.10.040","article-title":"Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model","volume":"47","author":"Redondo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/cn300105c","article-title":"Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice","volume":"3","author":"Redondo","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115194_bib52","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1021\/jm201720d","article-title":"Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds","volume":"55","author":"Redondo","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2016.11.027","article-title":"Phosphodiesterase-7 inhibition affects accumbal and hypothalamic thyrotropin-releasing hormone expression, feeding and anxiety behavior of rats","volume":"319","author":"Valdes-Moreno","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2023.115194_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015937","article-title":"PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury","volume":"6","author":"Paterniti","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115194_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","article-title":"Dual inhibitor of PDE7 and GSK-3 - VP1.15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice","volume":"64","author":"Lipina","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115194_bib56","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1021\/acs.jmedchem.5b01813","article-title":"PDEStrIAn: a phosphodiesterase structure and ligand interaction annotated database as a tool for structure-based drug design","volume":"59","author":"Jansen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib57","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/jm990382n","article-title":"Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors","volume":"43","author":"Martinez","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1871520620666200721104431","article-title":"Fused and substituted pyrimidine derivatives as profound anti-cancer agents","volume":"21","author":"Abbas","year":"2021","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib59","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0960-894X(01)00125-1","article-title":"Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors, Bioorg","volume":"11","author":"Barnes","year":"2001","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib60","doi-asserted-by":"crossref","first-page":"30949","DOI":"10.1074\/jbc.M504398200","article-title":"Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7","volume":"280","author":"Wang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib61","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.bmcl.2012.03.025","article-title":"Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation","volume":"22","author":"Banerjee","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib62","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1021\/jm701255b","article-title":"Ligand binding efficiency: trends, physical basis, and implications","volume":"51","author":"Reynolds","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib63","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bmcl.2014.11.090","article-title":"Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors","volume":"25","author":"Endo","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib64","article-title":"Natural quinazolinones: from a treasure house to promising anticancer leads","volume":"245","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib65","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1021\/acs.jmedchem.1c01577","article-title":"Boosting the discovery of small molecule inhibitors of glucose-6-phosphate dehydrogenase for the treatment of cancer, infectious diseases, and inflammation","volume":"65","author":"Koperniku","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmech.2019.03.018","article-title":"4(3H)-Quinazolinone derivatives: promising antibacterial drug leads","volume":"170","author":"Gatadi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113070","article-title":"4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: a promising scaffold towards bioactive molecules","volume":"213","author":"Plescia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib68","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.bmcl.2004.07.011","article-title":"Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1","volume":"14","author":"Lorthiois","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib69","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1016\/j.bmcl.2004.07.010","article-title":"Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: optimization of 5,8-disubstituted derivatives","volume":"14","author":"Bernardelli","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib70","series-title":"Preparation of Spirocyclic Derivatives as PDE7 Inhibitors","author":"Rawson","year":"2008"},{"key":"10.1016\/j.ejmech.2023.115194_bib71","series-title":"Substituted Benzoxazole and Benzofuran Compounds as PDE7 Inhibitors and Their Preparation","author":"Santora","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115194_bib72","series-title":"Spiroquinazoline-2-one Derivative, its Preparation Method from 2-aminoacetophenone Compound, 2-substituted Aminobenzaldehyde Compound and Iso(thio)cyanate Compound, and Application in Preparation of PDE7 Inhibitor","author":"Ma","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115194_bib73","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0352-4","article-title":"Amyloid \u03b2-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition","volume":"10","author":"Bartolome","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejmech.2023.115194_bib74","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5966\/sctm.2014-0277","article-title":"Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats","volume":"4","author":"Morales-Garcia","year":"2015","journal-title":"Stem. Cells Transl. Med."},{"key":"10.1016\/j.ejmech.2023.115194_bib75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000445295","article-title":"PDE7B, NMBR and EPM2A variants and schizophrenia: a case-control and pharmacogenetics study","volume":"73","author":"Porcelli","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejmech.2023.115194_bib76","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00018-013-1340-2","article-title":"Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival","volume":"70","author":"Medina-Rodriguez","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.115194_bib77","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bph.12308","article-title":"Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis","volume":"170","author":"Gonzalez-Garcia","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib78","series-title":"Quinazoline-2,4(1H,3H)-dione Derivatives, Their Preparation and Use as Phosphodiesterase, Especially PDE7, Inhibitors for Treating Inflammation, Diabetes, Psychiatric, Neurological and Cardiovascular Diseases","author":"Clauss","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115194_bib79","series-title":"S-Substituted Quinazolines for Therapeutic Application in Treating Diseases Mediated by Phosphodiesterase 7","author":"Gil Ayuso-Gontan","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115194_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100051","article-title":"Design, synthesis, and pharmacological characterization of some 2-substituted-3-phenyl-quinazolin-4(3H)-one derivatives as phosphodiesterase inhibitors","volume":"354","author":"Amin","year":"2021","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2023.115194_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900211","article-title":"Synthesis, biological screening, and molecular docking of quinazolinone and quinazolinethione as phosphodiesterase 7 inhibitors","volume":"353","author":"Elfeky","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2023.115194_bib82","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.1021\/jm9003957","article-title":"Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage","volume":"52","author":"Garcia","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib83","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.bmc.2013.01.067","article-title":"Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors","volume":"21","author":"Sanchez","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib84","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.bmcl.2004.03.021","article-title":"Identification of purine inhibitors of phosphodiesterase 7 (PDE7), Bioorg","volume":"14","author":"Pitts","year":"2004","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib85","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib86","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.bmcl.2005.02.025","article-title":"Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships","volume":"15","author":"Kempson","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib87","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1039\/C4OB00175C","article-title":"Microwave-assisted synthesis of potent PDE7 inhibitors containing a thienopyrimidin-4-amine scaffold","volume":"12","author":"Sanchez","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib88","series-title":"Ortega Preparation of 4-Aminothieno[2,3-D]pyrimidine-6-Carbonitrile Derivatives as PDE7 Inhibitors","author":"Terricabras Belart","year":"2004"},{"key":"10.1016\/j.ejmech.2023.115194_bib89","series-title":"PDE7 Inhibitor Comprising Bicyclic Nitrogenated Heterocyclic Compound","author":"Nakajima","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115194_bib90","series-title":"PDE7 Inhibitor Comprising Bicyclic Nitrogenated Heterocyclic Compound and Pharmaceutical Composition","author":"Nakajima","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115194_bib91","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.bmcl.2009.02.060","article-title":"Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation","volume":"19","author":"Guo","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib92","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.2174\/0929867325666180904125400","article-title":"Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents","volume":"26","author":"Chiacchio","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.869860","article-title":"Recent advances of pyridinone in medicinal chemistry","volume":"10","author":"Lin","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib94","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1016\/j.bmcl.2011.09.065","article-title":"Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors","volume":"21","author":"Gewald","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib95","doi-asserted-by":"crossref","first-page":"710","DOI":"10.17485\/ijst\/2010\/v3i7.1","article-title":"Evaluation of seizure activity after phospho-diesterase and adenylate cyclase inhibition (SQ22536) in animal models of epilepsy","volume":"3","author":"Nandhakumar","year":"2010","journal-title":"Indian J. Sci. Technol."},{"key":"10.1016\/j.ejmech.2023.115194_bib96","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/540S1a","article-title":"Multiple sclerosis","volume":"540","author":"Owens","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115194_bib97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.abm7930","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"375","author":"Robinson","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115194_bib98","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature01552","article-title":"Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis","volume":"422","author":"Pluchino","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115194_bib99","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/acschemneuro.0c00106","article-title":"PDE-7 inhibitor BRL-50481 reduces neurodegeneration and long-term memory deficits in mice following sevoflurane exposure","volume":"11","author":"Chen","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115194_bib100","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3390\/biomedicines10051192","article-title":"Alcohol use disorder: neurobiology and therapeutics","volume":"10","author":"Yang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2023.115194_bib101","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.jmedchem.7b00115","article-title":"Class I HDAC inhibitors: potential new epigenetic therapeutics for alcohol use disorder (AUD)","volume":"61","author":"Bourguet","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib102","first-page":"36","article-title":"Comparison of phosphodiesterase 7 expression in brain striatum of C57BL\/6J and DBA\/2J mice and association with ethanol drinking behavior","volume":"35","author":"Zhang","year":"2021","journal-title":"Zhongguo Yaolixue Yu Dulixue Zazhi"},{"key":"10.1016\/j.ejmech.2023.115194_bib103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12272-021-01367-x","article-title":"The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model","volume":"45","author":"Kim","year":"2022","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2023.115194_bib104","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s43440-020-00154-7","article-title":"Thiadiazole derivatives as anticancer agents","volume":"72","author":"Szeliga","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2023.115194_bib105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/13543776.2017.1272575","article-title":"Thiadiazole inhibitors: a patent review","volume":"27","author":"Dawood","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115194_bib106","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1016\/j.bmcl.2004.07.008","article-title":"Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies","volume":"14","author":"Vergne","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib107","series-title":"J. Brea Floriani Preparation of Substituted 5-Imino-1,2,4-Thiadiazoles as PDE7 Inhibitors for Treating Neurodegenerative Diseases","author":"Martinez Gil","year":"2011"},{"key":"10.1016\/j.ejmech.2023.115194_bib108","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1016\/j.bmcl.2004.07.009","article-title":"Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives","volume":"14","author":"Vergne","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib109","series-title":"Preparation of Thienopyrazole Derivatives as PDE7 Inhibitors","author":"Inoue","year":"2006"},{"key":"10.1016\/j.ejmech.2023.115194_bib110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cellimm.2009.04.005","article-title":"Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells","volume":"258","author":"Goto","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ejmech.2023.115194_bib111","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.intimp.2009.08.002","article-title":"Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice","volume":"9","author":"Goto","year":"2009","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115194_bib112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.imlet.2009.01.004","article-title":"ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes","volume":"122","author":"Kadoshima-Yamaoka","year":"2009","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2023.115194_bib113","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.intimp.2008.10.005","article-title":"Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte","volume":"9","author":"Kadoshima-Yamaoka","year":"2009","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115194_bib114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2009.04.014","article-title":"ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-\u03b1 level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in mice","volume":"613","author":"Kadoshima-Yamaoka","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejphar.2010.01.024","article-title":"Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo","volume":"633","author":"Goto","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115194_bib116","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational multitargeted drug design strategy from the perspective of a medicinal chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib117","series-title":"Preparation of Phthalazinones as Phosphodiesterase 4\/7 Inhibitors","author":"Hatzelmann","year":"2002"},{"key":"10.1016\/j.ejmech.2023.115194_bib118","series-title":"Isochromenones as PDE4 and PDE7 Inhibitors and Their Preparation and Use in the Treatment of Inflammation","author":"Pelcman","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115194_bib119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cellsig.2017.08.011","article-title":"Identification and characterization of a potent and biologically-active PDE4\/7 inhibitor via fission yeast-based assays","volume":"40","author":"Santos de Medeiros","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2023.115194_bib120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejmech.2018.01.068","article-title":"Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4\/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation","volume":"146","author":"Chlon-Rzepa","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105409","article-title":"Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents","volume":"117","author":"Wojcik-Pszczola","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112854","article-title":"New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases","volume":"209","author":"Rucilova","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115194_bib123","series-title":"Quinazolinedione Derivatives as PDE Inhibitors and Their Preparation and Use in the Treatment of Central and Peripheral Nervous System Disorder","author":"Marciniak","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115194_bib124","series-title":"Quinazolinedione Derivatives as PDE Inhibitors and Their Preparation and Use in the Treatment of Central and Peripheral Nervous System Disorder","author":"Marciniak","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115194_bib125","series-title":"Quinazolinedione Derivatives as PDE Inhibitors and Their Preparation and Use in the Treatment of Cardiovascular Diseases","author":"Janiak","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115194_bib126","series-title":"Quinazolinedione Derivatives, Their Preparation and Their Therapeutic Applications as PDE7 Inhibitors and in Select Cases as PDE8 Inhibitors","author":"Clauss","year":"2009"},{"key":"10.1016\/j.ejmech.2023.115194_bib127","series-title":"Quinazolinedione Derivatives, Their Preparation and Their Therapeutic Applications as PDE7 Inhibitors","author":"Clauss","year":"2009"},{"key":"10.1016\/j.ejmech.2023.115194_bib128","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/jid.2010.62","article-title":"Cyclic AMP suppresses matrix metalloproteinase-1 expression through inhibition of MAPK and GSK-3beta","volume":"130","author":"Park","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2023.115194_bib129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1160\/TH08-12-0781","article-title":"Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets","volume":"102","author":"Hayashi","year":"2009","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2023.115194_bib130","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1471-4159.2012.07866.x","article-title":"The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury","volume":"122","author":"Susin","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2023.115194_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/srep43545","article-title":"Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis","volume":"7","author":"Medina-Rodriguez","year":"2017","journal-title":"Sci. Rep."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:01Z","timestamp":1759330201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":131,"alternative-id":["S0223523423001095"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115194","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the development of phosphodiesterase 7 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115194"}}